logo
A.I. Start-Up Perplexity Offers to Buy Google's Chrome Browser for $34.5 Billion

A.I. Start-Up Perplexity Offers to Buy Google's Chrome Browser for $34.5 Billion

New York Times2 days ago
In an unlikely bid that shows the growing brashness of young artificial intelligence companies, the A.I. start-up Perplexity has made an unsolicited offer to buy Google's Chrome web browser for $34.5 billion.
The tiny company made its offer against the backdrop of an upcoming antitrust decision against the tech giant. In a ruling due as early as this week, U.S. District Judge Amit Mehta could force Google to sell its web browser as a way of reducing the company's dominance in the internet search market.
The Perplexity chief executive, Aravind Srinivas, said in a letter to Sundar Pichai, chief executive of Google's parent company, Alphabet, that its offer to buy the Chrome browser was 'designed to satisfy an antitrust remedy in highest public interest by placing Chrome with a capable, independent operator.'
Google did not immediately respond to a request for comment. Perplexity's offer was previously reported by The Wall Street Journal.
Perplexity is among the many companies that want to challenge Google's search engine through online chatbots and similar technologies that respond to queries with short sentences rather than just a list of links. The Chrome browser could give it an edge among Google's many challengers, including Microsoft, OpenAI and the Silicon Valley start-up You.com.
But the unsolicited bid is a long shot, since Perplexity itself is valued at an estimated $18 billion. Jesse Dwyer, a spokesman for the company, told The New York Times that outside investors had agreed to back a potential deal.
Judge Mehta ruled last year that Google had violated antitrust rules to maintain its dominance in the search market.
The Justice Department has pushed for a federal court to force Google to sell its Chrome browser in a series of aggressive remedy proposals after prevailing in its antitrust case against the search giant. The department has argued that forcing Google to divest Chrome and share search results and ads with rivals would create more competition.
The government told Judge Mehta that Google's monopoly — it controls about 90 percent of the search market — cannot be remedied without forceful structural changes to the company. And without a remedy like the sale of Chrome, Google was poised to dominate A.I., the government argued.
'This court's remedy should be forward looking and not ignore what's on the horizon,' said David Dahlquist, the government's lead litigator. 'Google is using the same strategy that they did for search and now applying it to Gemini,' he added, referring to Google's A.I. technology.
Google has argued against the sale of Chrome, proposing smaller tweaks to its business model. Perplexity and other A.I. companies testified in April during the antitrust remedies hearing by Judge Mehta that it was interested in buying Chrome.
Perplexity was founded in 2022 by a group of A.I. researchers including Mr. Srinivas, who previously worked at OpenAI. In an effort to boost usage of its A.I.-powered search engine, the company has started to offer a web browser of its own, called Comet.
The New York Times sent Perplexity a cease and desist letter last year demanding that the company stop using its content to help power its A.I. technologies.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi
Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

Yahoo

time12 minutes ago

  • Yahoo

Hudbay Minerals (HBM) Climbs 15% on Stellar Earnings, $600-Million Investment From Mitsubishi

We recently published . Hudbay Minerals Inc. (NYSE:HBM) is one of the best-performing stocks on Wednesday. Hudbay Minerals grew its share prices for a second day on Wednesday, up 15.03 percent to close at $11.33 apiece, following an impressive earnings performance and a $600-million investment from Mitsubishi Corp. In its updated report, Hudbay Minerals Inc. (NYSE:HBM) said it swung to a net income attributable to shareholders of $117.7 million from an attributable net loss of $16.5 million in the same period last year, driven by higher gross margins and strong cost control. Revenues increased by 26 percent to $536.4 million from $425.5 million year-on-year. 'With the strong performance in the first half of the year, we are reaffirming our full year consolidated production guidance and are favourably tracking well below our full year consolidated cost guidance for 2025,' said Hudbay Minerals Inc. (NYSE:HBM) President and CEO Peter Kukielski. For the full-year period, the company is targeting to produce between 117,000 and 149,000 tons of copper, as well as 247,500 to 308,000 ounces of gold. In other news, Hudbay Minerals Inc. (NYSE:HBM) was able to raise $600 million in fresh funds from Mitsubishi Corp. after the latter acquired a 30-percent stake in Copper World LLC. Under the agreement, Mitsubishi will pay an upfront cash of $420 million, with the balance to serve as a matching contribution within an 18-month period. While we acknowledge the potential of HBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

Yahoo

time12 minutes ago

  • Yahoo

Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?

We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

Yahoo

time12 minutes ago

  • Yahoo

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store